Pulmonx Corporation updated its revenue guidance for fiscal year 2023. For the period, the company is increasing its expectation to now range from $64 million to $66 million, which represents approximately 19% to 23% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $63 million to $65 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.07 USD | -3.70% | -10.33% | -36.71% |
05-01 | Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M | MT |
05-01 | Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.71% | 313M | |
+75.35% | 12.55B | |
-23.01% | 7.51B | |
+8.35% | 6.74B | |
+14.40% | 5.47B | |
-14.85% | 4.89B | |
+32.74% | 4.74B | |
-25.57% | 3.7B | |
-23.06% | 2.9B | |
+55.06% | 2.49B |
- Stock Market
- Equities
- LUNG Stock
- News Pulmonx Corporation
- Pulmonx Corporation Updates Revenue Guidance for Fiscal Year 2023